Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells

Cancer Research

Volumn 61, Issue 7, 2001, Pages 2961-2967

  Larsen, Annette K ^a   Gilbert, Cristèle ^a   Chyzak, Ginette ^a   Plisov, Sergey Y ^a   Naguibneva, Irina ^a   Lavergne, Olivier ^b   Lesueur Ginot, Laurence ^b   Bigg, Dennis C H ^b  

^a CNRS   (France)

^b Institut Henri Beaufour   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DNA TOPOISOMERASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; DNA PROTEIN COMPLEX; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CACO-2 CELLS; CAMPTOTHECIN; CELL DIVISION; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA, SUPERHELICAL; GROWTH INHIBITORS; HT29 CELLS; HUMANS; KINETICS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 0035300590     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
2. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
3. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin
4. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
5. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC-3F cells
6. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografs
7. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
8. DNA topoisomerase I, a new target for the treatment of neuroblastoma
9. Setting a new standard-irinotecan (Campto) in the second-line therapy of colorectal cancer: Final results of two Phase III studies and implications for clinical practice
10. Topotecan: An oncologist's view
11. Topoisomerase I inhibitors: Review and update
12. The other camptothecins: Recent advances with camptothecin analogues other than irinotecan and topotecan
13. Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity
14. Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis. In vitro pharmacokinetics, toxicity, and antitumor activity
15. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
16. Structural modifications of camptothecin and effects on topoisomerase I inhibition
17. Synthesis of 18-noranhydrocamptothecin analogues which retain topoisomerase I inhibitory function
18. Camptothecin, and taxol: Discovery to clinic. Thirteenth Bruce F. Cain Memorial Award Lecture
19. BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities
20. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
21. Homocamptothecins: Synthesis and antitumor activity of novel E-ring modified camptothecin analogues
22. Specific phosphorylation of SR proteins by mammalian topoisomerase I
23. Circular dichroism and temperature-optical density studies on the conformation of polynucleotide-ethidium bromide complexes
24. Distribution of intercalative dye binding sites in chromatin
25. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
26. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II
27. Analysis of topoisomerase I/DNA complexes in patients administered topotecan
28. Ultraviolet-induced, DNA damage stimulates topoisomerase I-DNA complex formation in vivo: Possible relationship with DNA repair
29. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II
30. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors
31. Acquired multicellular mediated resistance to alkylating agents in cancer
32. Homocamptothecin, an E-ring modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks
33. Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death
34. Isolation and characterization of an anthracycline-resistant human leukemic cell line
35. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression
36. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells
37. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells
38. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
39. An E-ring modified camptothecin, BN 80915, shows unusual stability and high activity both in vitro and in vivo
40. Novel A, B, E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities
41. DNA interactions of two clinical camptothecin drugs stabilize their active lactone form
42. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
43. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage
44. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes
45. Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity
46. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan
47. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport
48. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P
49. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines